These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 22492229)

  • 1. A role of the mammalian target of rapamycin (mTOR) in glutamate-induced down-regulation of tuberous sclerosis complex proteins 2 (TSC2).
    Ru W; Peng Y; Zhong L; Tang SJ
    J Mol Neurosci; 2012 Jun; 47(2):340-5. PubMed ID: 22492229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tuberous sclerosis-2 (TSC2) regulates the stability of death-associated protein kinase-1 (DAPK) through a lysosome-dependent degradation pathway.
    Lin Y; Henderson P; Pettersson S; Satsangi J; Hupp T; Stevens C
    FEBS J; 2011 Jan; 278(2):354-70. PubMed ID: 21134130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fetal brain mTOR signaling activation in tuberous sclerosis complex.
    Tsai V; Parker WE; Orlova KA; Baybis M; Chi AW; Berg BD; Birnbaum JF; Estevez J; Okochi K; Sarnat HB; Flores-Sarnat L; Aronica E; Crino PB
    Cereb Cortex; 2014 Feb; 24(2):315-27. PubMed ID: 23081885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tuberous sclerosis complex activity is required to control neuronal stress responses in an mTOR-dependent manner.
    Di Nardo A; Kramvis I; Cho N; Sadowski A; Meikle L; Kwiatkowski DJ; Sahin M
    J Neurosci; 2009 May; 29(18):5926-37. PubMed ID: 19420259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tuberous sclerosis complex suppression in cerebellar development and medulloblastoma: separate regulation of mammalian target of rapamycin activity and p27 Kip1 localization.
    Bhatia B; Northcott PA; Hambardzumyan D; Govindarajan B; Brat DJ; Arbiser JL; Holland EC; Taylor MD; Kenney AM
    Cancer Res; 2009 Sep; 69(18):7224-34. PubMed ID: 19738049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Akt activates the mammalian target of rapamycin by regulating cellular ATP level and AMPK activity.
    Hahn-Windgassen A; Nogueira V; Chen CC; Skeen JE; Sonenberg N; Hay N
    J Biol Chem; 2005 Sep; 280(37):32081-9. PubMed ID: 16027121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of mechanically regulated phosphorylation sites on tuberin (TSC2) that control mechanistic target of rapamycin (mTOR) signaling.
    Jacobs BL; McNally RM; Kim KJ; Blanco R; Privett RE; You JS; Hornberger TA
    J Biol Chem; 2017 Apr; 292(17):6987-6997. PubMed ID: 28289099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin like growth factor-1-induced phosphorylation and altered distribution of tuberous sclerosis complex (TSC)1/TSC2 in C2C12 myotubes.
    Miyazaki M; McCarthy JJ; Esser KA
    FEBS J; 2010 May; 277(9):2180-91. PubMed ID: 20412061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The tuberous sclerosis protein TSC2 is not required for the regulation of the mammalian target of rapamycin by amino acids and certain cellular stresses.
    Smith EM; Finn SG; Tee AR; Browne GJ; Proud CG
    J Biol Chem; 2005 May; 280(19):18717-27. PubMed ID: 15772076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of combined inhibition of mTOR and ERK/MAPK pathways in treating a tuberous sclerosis complex cell model.
    Mi R; Ma J; Zhang D; Li L; Zhang H
    J Genet Genomics; 2009 Jun; 36(6):355-61. PubMed ID: 19539245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon beta augments tuberous sclerosis complex 2 (TSC2)-dependent inhibition of TSC2-null ELT3 and human lymphangioleiomyomatosis-derived cell proliferation.
    Goncharova EA; Goncharov DA; Chisolm A; Spaits MS; Lim PN; Cesarone G; Khavin I; Tliba O; Amrani Y; Panettieri RA; Krymskaya VP
    Mol Pharmacol; 2008 Mar; 73(3):778-88. PubMed ID: 18094073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. mTOR-dependent regulation of PHLPP expression controls the rapamycin sensitivity in cancer cells.
    Liu J; Stevens PD; Gao T
    J Biol Chem; 2011 Feb; 286(8):6510-20. PubMed ID: 21177869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced expression of glucose transporter-1 in vascular smooth muscle cells via the Akt/tuberous sclerosis complex subunit 2 (TSC2)/mammalian target of rapamycin (mTOR)/ribosomal S6 protein kinase (S6K) pathway in experimental renal failure.
    Lin CY; Hsu SC; Lee HS; Lin SH; Tsai CS; Huang SM; Shih CC; Hsu YJ
    J Vasc Surg; 2013 Feb; 57(2):475-85. PubMed ID: 23265586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dysregulation of autophagy in melanocytes contributes to hypopigmented macules in tuberous sclerosis complex.
    Yang F; Yang L; Wataya-Kaneda M; Hasegawa J; Yoshimori T; Tanemura A; Tsuruta D; Katayama I
    J Dermatol Sci; 2018 Feb; 89(2):155-164. PubMed ID: 29146131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. mTOR Hyperactivation by Ablation of Tuberous Sclerosis Complex 2 in the Mouse Heart Induces Cardiac Dysfunction with the Increased Number of Small Mitochondria Mediated through the Down-Regulation of Autophagy.
    Taneike M; Nishida K; Omiya S; Zarrinpashneh E; Misaka T; Kitazume-Taneike R; Austin R; Takaoka M; Yamaguchi O; Gambello MJ; Shah AM; Otsu K
    PLoS One; 2016; 11(3):e0152628. PubMed ID: 27023784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapamycin-insensitive up-regulation of MMP2 and other genes in tuberous sclerosis complex 2-deficient lymphangioleiomyomatosis-like cells.
    Lee PS; Tsang SW; Moses MA; Trayes-Gibson Z; Hsiao LL; Jensen R; Squillace R; Kwiatkowski DJ
    Am J Respir Cell Mol Biol; 2010 Feb; 42(2):227-34. PubMed ID: 19395678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapamycin reverses impaired social interaction in mouse models of tuberous sclerosis complex.
    Sato A; Kasai S; Kobayashi T; Takamatsu Y; Hino O; Ikeda K; Mizuguchi M
    Nat Commun; 2012; 3():1292. PubMed ID: 23250422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urokinase-type plasminogen activator (uPA) is critical for progression of tuberous sclerosis complex 2 (TSC2)-deficient tumors.
    Stepanova V; Dergilev KV; Holman KR; Parfyonova YV; Tsokolaeva ZI; Teter M; Atochina-Vasserman EN; Volgina A; Zaitsev SV; Lewis SP; Zabozlaev FG; Obraztsova K; Krymskaya VP; Cines DB
    J Biol Chem; 2017 Dec; 292(50):20528-20543. PubMed ID: 28972182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TSC2 regulates VEGF through mTOR-dependent and -independent pathways.
    Brugarolas JB; Vazquez F; Reddy A; Sellers WR; Kaelin WG
    Cancer Cell; 2003 Aug; 4(2):147-58. PubMed ID: 12957289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rheb binds tuberous sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a rapamycin- and farnesylation-dependent manner.
    Castro AF; Rebhun JF; Clark GJ; Quilliam LA
    J Biol Chem; 2003 Aug; 278(35):32493-6. PubMed ID: 12842888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.